ClinicalTrials.gov record NCT07591844

Effect of Periodontal Therapy on Asprosin in Stable Angina

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 6, 2026

Effect of Non-Surgical Periodontal Therapy on Serum Asprosin in Patients With Stable Angina

StatusNot yet recruitingThe study has been registered but has not started enrolling. Sites and contacts may not be listed yet.
Study typeInterventionalA study in which researchers assign participants to one or more interventions, such as a drug, procedure, device, behavioural programme or other approach, to measure their effects.
Healthy volunteersAcceptedPeople who do not have the condition being studied who are allowed to take part. Some studies include both people with the condition and healthy volunteers; others may enrol only healthy volunteers.
Age18 years old and older
SexAll
LocationTurkey
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This randomized, open-label study compares non-surgical periodontal therapy with routine dental cleaning in three groups: healthy controls, people with periodontitis, and people with both stable angina and periodontitis. The study measures serum asprosin at the start and again at 3 months to see if levels change after treatment. Clinical periodontal measures will also be recorded to examine relationships with asprosin.

What it is studying. The study is testing whether non-surgical periodontal therapy (scaling and root planing) affects blood (serum) levels of the adipokine protein asprosin. It also looks for links between changes in periodontal health (gum disease measurements) and serum asprosin before and three months after treatment.

What the researchers hope to learn. To determine whether periodontal therapy changes serum asprosin levels and to explore the relationship between periodontal inflammation and metabolic-inflammatory pathways relevant to cardiovascular disease.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

This study aims to evaluate the effect of non-surgical periodontal therapy on serum asprosin levels in patients with stable angina and periodontitis. Asprosin is a novel metabolic biomarker reported to have potential protective roles in cardiovascular diseases and inflammatory processes. The study also investigates the relationship between periodontal parameters and serum asprosin levels before and after periodontal therapy.

Interventions being studied

Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.

Procedure
  • Non-surgical periodontal therapy (scaling and root planing)
  • Non-surgical periodontal therapy (Professional dental cleaning)

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

  • Willingness to participate in the study and provide written informed consent
  • Age 18 years or older
  • No periodontal treatment within the past 6 months
  • No use of local or systemic antibiotics within the past 3 months

Exclusion criteria

  • Unwillingness to participate in the study or to provide informed consent
  • Age under 18 years
  • Use of local or systemic antibiotics for the treatment of widespread infection within the past 3 months
  • Receipt of periodontal treatment within the past 6 months
  • Pregnancy or lactation (for female participants)
  • History of acute myocardial infarction within the past 6 months

Study description and what participation involves

The study's detailed description, as published on ClinicalTrials.gov.

Show the detailed description from the registry

Periodontitis is a chronic inflammatory disease characterized by the destruction of the tooth-supporting tissues and has been associated with increased systemic inflammation and cardiovascular diseases. Stable angina, a clinical manifestation of coronary artery disease, is closely linked to inflammatory and metabolic pathways. Increasing evidence suggests that periodontal inflammation may contribute to cardiovascular pathology through systemic dissemination of inflammatory mediators and oxidative stress mechanisms. Asprosin is a recently identified adipokine secreted mainly from white adipose tissue and is involved in glucose metabolism, inflammatory regulation, and cardiovascular homeostasis. Previous studies have reported altered serum asprosin levels in patients with atherosclerosis, myocardial infarction, and periodontitis. However, the effect of periodontal therapy on serum asprosin levels in patients with stable angina has not yet been clinically investigated. In this clinical study, 60 individuals will be allocated into three groups: healthy controls, periodontitis patients, and patients with stable angina and periodontitis. Non-surgical periodontal therapy will be performed in periodontitis groups, while supragingival scaling and oral hygiene instructions will be provided for controls. Clinical periodontal parameters and serum asprosin levels will be evaluated at baseline and at 3-month follow-up using ELISA analysis. The study aims to determine whether periodontal therapy may influence serum asprosin levels and to evaluate the possible relationship between periodontal inflammation and metabolic-inflammatory pathways in cardiovascular disease. To the best of our knowledge, this is the first clinical study evaluating the effect of periodontal therapy on serum asprosin levels in patients with stable angina.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

After giving informed consent, participants are randomly assigned to one of three groups. Those with periodontitis receive non-surgical periodontal therapy (scaling and root planing); controls receive professional dental cleaning and standardized oral hygiene instruction. Clinical periodontal exams and blood draws for serum asprosin measurement are done at baseline and again at 3 months. No other invasive procedures are described in the registry.

How the study is structured. Participants are randomly assigned to one of three groups (parallel design) and the study is not masked (open-label). Two groups with periodontitis receive full-mouth non-surgical periodontal therapy (scaling and root planing); the control group receives professional dental cleaning and oral hygiene instruction. Blood samples and periodontal exams are done at baseline and at a 3-month follow-up; serum asprosin will be measured using an ELISA test.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

  • The registry lists this study under Stable Angina Pectoris; Periodontitis. Does it apply to my diagnosis?
  • The registry says recruitment has not started. When is it expected to open, and can I register interest now?
  • The listed sites are in Turkey. Is any of them reachable for me, and does the study help with travel?
  • Which of the eligibility criteria would need to be checked with tests before I could join?

More on Marfan syndrome

Clinical trials20 trials listed for Marfan syndromeEvery trial the registry lists for Marfan syndrome, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in Marfan syndrome researchLatest monthly update: September 2026. Includes: After open aortic repair. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start
May 20, 2026 (estimated)
Primary completion
Aug 20, 2026 (estimated)
Study completion
Oct 20, 2026 (estimated)
Target enrollment
60 participants (estimated)
Last updated on registry
May 18, 2026
Data verified
Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor
Ondokuz Mayıs University
Principal investigator
Sena Altintas, Research assistant
Ondokuz Mayıs University

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Participating sites (1)

Terms used on this page · explanations by MedicalUpdates.ai

biomarker
Something measurable in the body, such as a blood test result or an imaging finding, that indicates how a condition or treatment is behaving.
written informed consent
The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
Inclusion Criteria
The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria
The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.
baseline
Measurements taken at the start of the study, before any study treatment, so that later results can be compared with them.
follow-up
The period after treatment or enrolment during which participants are observed or contacted, for example to record side effects or outcomes.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials